{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:24:23Z","timestamp":1787757863067,"version":"build-2784847793"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,5]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>The combination of diphenylcyclopropenone (DCP) and anthralin may demonstrate synergistic effects in the treatment of chronic extensive alopecia areata (AA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>The objective of the study was to compare the efficacy of the combination therapy of topical DCP and topical 0.5% anthralin versus topical DCP alone for the treatment of chronic extensive AA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>Ten patients were included in the study. Of these, 1, 2, and 7 patients were diagnosed with alopecia totalis, severe AA (&gt;50% hair loss), and alopecia universalis, respectively. For each patient, one side of the scalp was treated with a DCP solution and 0.5% anthralin for 6 months, while the other side was treated with DCP and a cream base for the same duration. The clinical responses were assessed at baseline and then monthly until the end of the 6-month study period using the Severity of Alopecia Tool score. The side effects were evaluated at each follow-up visit.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      The difference in the efficacies of the combination treatment and DCP alone was not statistically significant (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.59). Regarding the side effects, DCP plus 0.5% anthralin caused significantly more excessive dermatitis than DCP alone (7 patients vs. 2 patients;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.02). Eight patients reported temporary hyperpigmentation at the combination-treatment site, whereas no hyperpigmentation was reported at the DCP-alone site of any patient (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>The combination of DCP and 0.5% anthralin was not superior to DCP alone for the treatment of chronic extensive AA. An increase in side effects \u2013 excessive dermatitis and hyperpigmentation \u2013 was observed in the combination-treatment group.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijt.ijt_72_21","type":"journal-article","created":{"date-parts":[[2022,5,24]],"date-time":"2022-05-24T09:26:44Z","timestamp":1653384404000},"page":"91-96","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Topical diphenylcyclopropenone plus topical 0.5% anthralin versus topical diphenylcyclopropenone alone for the treatment of chronic extensive alopecia areata"],"prefix":"10.4103","volume":"14","author":[{"given":"Rattapon","family":"Thuangtong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saroj","family":"Suvansuthi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pitchaya","family":"Maneeprasopchoke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thanisorn","family":"Sukakul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rattiya","family":"Techakajornkeart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pichanee","family":"Chaweekulrat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Supisara","family":"Wongdama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daranporn","family":"Triwongwaranat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-3-20240903","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.jaad.2009.10.032","article-title":"Alopecia areata update: Part I. Clinical picture, histopathology, and pathogenesis","volume":"62","author":"Alkhalifah","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"R2-3-20240903","doi-asserted-by":"crossref","first-page":"296","DOI":"10.2340\/0001555577296298","article-title":"Stress and alopecia areata: A psychodermatologic study","volume":"77","author":"Gupta","year":"1997","journal-title":"Acta Derm Venereol"},{"key":"R3-3-20240903","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1038\/jidsymp.2013.14","article-title":"Current treatment of alopecia areata","volume":"16","author":"Shapiro","year":"2013","journal-title":"J Investig Dermatol Symp Proc"},{"key":"R4-3-20240903","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.jaad.2006.05.008","article-title":"Alopecia areata: A long term follow-up study of 191 patients","volume":"55","author":"Tosti","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"R5-3-20240903","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.jaad.2008.08.045","article-title":"Acute diffuse and total alopecia: A new subtype of alopecia areata with a favorable prognosis","volume":"60","author":"Lew","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"R6-3-20240903","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jaad.2009.10.031","article-title":"Alopecia areata update: Part II. Treatment","volume":"62","author":"Alkhalifah","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"R7-3-20240903","first-page":"537","article-title":"Diphenylcyclopropenone treatment of alopecia areata induces apoptosis of perifollicular lymphocytes","volume":"16","author":"Herbst","year":"2006","journal-title":"Eur J Dermatol"},{"key":"R8-3-20240903","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1111\/ijd.13612","article-title":"Review of treatment for alopecia totalis and alopecia universalis","volume":"56","author":"Kassira","year":"2017","journal-title":"Int J Dermatol"},{"key":"R9-3-20240903","first-page":"48","article-title":"Topical immunotherapy with diphenylcyclopropenone in the treatment of chronic extensive alopecia areata","volume":"32","author":"Sotiriadis","year":"2007","journal-title":"Clin Exp Dermatol"},{"key":"R10-3-20240903","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1002\/jlb.64.2.170","article-title":"Antioxidants attenuate anthralin-induced skin inflammation in BALB\/c mice: Role of specific proinflammatory cytokines","volume":"64","author":"Lange","year":"1998","journal-title":"J Leukoc Biol"},{"key":"R11-3-20240903","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.0906-6705.2004.00098.x","article-title":"Restoration of hair growth in mice with an alopecia areata-like disease using topical anthralin","volume":"13","author":"Tang","year":"2004","journal-title":"Exp Dermatol"},{"key":"R12-3-20240903","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1001\/archderm.1987.01660350091020","article-title":"Evaluation of anthralin in the treatment of alopecia areata","volume":"123","author":"Fiedler-Weiss","year":"1987","journal-title":"Arch Dermatol"},{"key":"R13-3-20240903","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1001\/archderm.1990.01670300056006","article-title":"Treatment-resistant alopecia areata. Response to combination therapy with minoxidil plus anthralin","volume":"126","author":"Fiedler","year":"1990","journal-title":"Arch Dermatol"},{"key":"R14-3-20240903","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/S0190-9622(99)70195-7","article-title":"Alopecia areata investigational assessment guidelines. National Alopecia Areata Foundation","volume":"40","author":"Olsen","year":"1999","journal-title":"J Am Acad Dermatol"},{"key":"R15-3-20240903","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/j.1468-3083.2011.04114.x","article-title":"Topical immunotherapy with diphenylcyclopropenone of patients with alopecia areata \u2013 A large retrospective study on 142 patients with a self-controlled design","volume":"26","author":"Ohlmeier","year":"2012","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R16-3-20240903","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/jidsymp.2015.28","article-title":"Clinical efficacy of diphenylcyclopropenone in alopecia areata: Retrospective data analysis of 50 patients","volume":"17","author":"Chiang","year":"2015","journal-title":"J Investig Dermatol Symp Proc"},{"key":"R17-3-20240903","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.jaad.2015.01.008","article-title":"Efficacy and safety of diphenylcyclopropenone alone or in combination with anthralin in the treatment of chronic extensive alopecia areata: A retrospective case series","volume":"72","author":"Durdu","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"R18-3-20240903","doi-asserted-by":"crossref","first-page":"577","DOI":"10.5114\/ada.2018.77608","article-title":"Efficacy of diphenylcyclopropenone in alopecia areata: A comparison of two treatment regimens","volume":"35","author":"Nowicka","year":"2018","journal-title":"Postepy Dermatol Alergol"},{"key":"R19-3-20240903","doi-asserted-by":"crossref","first-page":"e14447","DOI":"10.1111\/dth.14447","article-title":"Limited efficacy of diphenylcyclopropenone in the treatment of alopecia areata: Experience from a Tertiary Healthcare Institution in Singapore","volume":"33","author":"Leong","year":"2020","journal-title":"Dermatol Ther"},{"key":"R20-3-20240903","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.jaad.2017.03.015","article-title":"Systematic review and quality analysis of studies on the efficacy of topical diphenylcyclopropenone treatment for alopecia areata","volume":"77","author":"Jang","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"R21-3-20240903","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1001\/jamadermatol.2018.2312","article-title":"Hair regrowth outcomes of contact immunotherapy for patients with alopecia areata: A systematic review and meta-analysis","volume":"154","author":"Lee","year":"2018","journal-title":"JAMA Dermatol"},{"key":"R22-3-20240903","doi-asserted-by":"crossref","first-page":"80","DOI":"10.4103\/0974-7753.90807","article-title":"Extensive alopecia areata: Not necessarily recalcitrant to therapy!","volume":"3","author":"Deshpande","year":"2011","journal-title":"Int J Trichology"},{"key":"R23-3-20240903","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s00403-019-01940-x","article-title":"Efficacy and safety of anthralin in combination with diphenylcyclopropenone in the treatment of alopecia areata: A retrospective case series","volume":"311","author":"Nasimi","year":"2019","journal-title":"Arch Dermatol Res"},{"key":"R24-3-20240903","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1111\/jocd.13588","article-title":"Topical immunotherapy in combination with anthralin in the treatment of refractory alopecia areata","volume":"19","author":"Kagami","year":"2020","journal-title":"J Cosmet Dermatol"},{"key":"R25-3-20240903","doi-asserted-by":"crossref","first-page":"e13010","DOI":"10.1111\/dth.13010","article-title":"Treatment of chronic extensive alopecia areata by diphenylcyclopropenone alone versus in combination with anthralin","volume":"32","author":"Ibrahim","year":"2019","journal-title":"Dermatol Ther"},{"key":"R26-3-20240903","doi-asserted-by":"crossref","first-page":"17011","DOI":"10.1038\/nrdp.2017.11","article-title":"Alopecia areata","volume":"3","author":"Pratt","year":"2017","journal-title":"Nat Rev Dis Primers"}],"container-title":["International Journal of Trichology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijt.ijt_72_21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T14:55:24Z","timestamp":1787756124000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijt.ijt_72_21"}},"subtitle":["A split-scalp, double-blind, controlled study"],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.4103\/ijt.ijt_72_21","relation":{},"ISSN":["0974-7753"],"issn-type":[{"value":"0974-7753","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]}}}